The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease

Leukemia Research

Volumn 34, Issue 3, 2010, Pages 294-300

  Park, Yong ^a   Kim, Dae Sik ^a   Park, Seh Jong ^a   Seo, Hee Yun ^a   Lee, Se Ryeon ^a   Sung, Hwa Jung ^a   Park, Kyong Hwa ^a   Choi, In Keun ^a   Kim, Seok Jin ^b   Oh, Sang Cheul ^a   Seo, Jae Hong ^a   Choi, Chul Won ^a   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a  

^a Korea University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Albumin; Bicarbonate; C reactive protein; Febrile neutropenia; Hematologic malignancy; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; BICARBONATE; C REACTIVE PROTEIN; CEFEPIME; GRANULOCYTE COLONY STIMULATING FACTOR; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIUM ISOLATE; COMORBIDITY; DIABETES MELLITUS; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEUKEMIA; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK; STRATIFICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUTROPENIA; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 77649189452     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.024     Document Type: Article

References (46)

1. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
2. Elting L.S., Rubenstein E.B., Rolston K.V., Bodey G.P. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997, 25:247-259.
3. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
4. Klastersky J., Paesmans M., Rubenstein E.B., Boyer M., Elting L., Feld R., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-3051.
5. Talcott J.A., Siegel R.D., Finberg R., Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992, 10:316-322.
6. Girmenia C., Russo E., Carmosino I., Breccia M., Dragoni F., Latagliata R., et al. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 2007, 86:263-270.
7. Klastersky J., Paesmans M., Georgala A., Muanza F., Plehiers B., Dubreucq L., et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006, 24:4129-4134.
8. Innes H., Marshall E. Outpatient therapy for febrile neutropenia. Curr Opin Oncol 2007, 19:294-298.
9. Yoo J.H., Choi S.M., Lee D.G., Choi J.H., Shin W.S., Min W.S., et al. Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci 2005, 20:31-35.
10. Ramzi J., Mohamed Z., Yosr B., Karima K., Raihane B., Lamia A., et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology 2007, 12:543-548.
11. Baskaran N.D., Gan G.G., Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 2008, 87:563-569.
12. Klastersky J., Ameye L., Maertens J., Georgala A., Muanza F., Aoun M., et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007, 30(Suppl 1):S51-S59.
13. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999, 29:490-494.
14. Gencer S., Salepci T., Ozer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J Infect 2003, 47:65-72.
15. Akova M. Emerging problem pathogens: a review of resistance patterns over time. Int J Infect Dis 2006, 10(Suppl 2):S3-8.
16. Viscoli C., Cometta A., Kern W.V., Bock R., Paesmans M., Crokaert F., et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006, 12:212-216.
17. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998, 41(Suppl D):13-24.
18. Calandra T. Vancomycin added to empirical combination antibiotictherapy for fever in granulocytopenic cancer patients. J Infect Dis 1991, 163:951-958.
19. Lai C.H., Chi C.Y., Chen H.P., Chen T.L., Lai C.J., Fung C.P., et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004, 37:350-358.
20. Chen H.P., Chen T.L., Lai C.H., Fung C.P., Wong W.W., Yu K.W., et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005, 38:127-136.
21. Romanov Y.A., Chervontseva A.M., Savchenko V.G., Smirnov V.N. Vascular endothelium: target or victim of cytostatic therapy?. Can J Physiol Pharmacol 2007, 85:396-403.
22. Guillot B., Bessis D., Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf 2004, 3:579-587.
23. Pedersen L.M., Terslev L.P.G.S.L., Stokholm K.H. Urinary albumin excretion and transcapillary escape rate of albumin in malignancies. Med Oncol 2000, 17:117-122.
24. Alexandre J., Gross-Goupil M., Falissard B., Nguyen M.L., Gornet J.M., Misset J.L., et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003, 14:36-41.
25. Slaviero K.A., Clarke S.J., Rivory L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003, 4:224-232.
26. Drisko J.A., Chapman J., Hunter V.J. The use of antioxidant therapies during chemotherapy. Gynecologic Oncol 2003, 88:434-439.
27. Goldwasser P., Feldman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997, 50:693-703.
28. Park M., Azevedo L.C., Maciel A.T., Pizzo V.R., Noritomi D.T., da Cruz Neto L.M. Evolutive standard base excess and serum lactate level in severe sepsis and septic shock patients resuscitated with early goal-directed therapy: still outcome markers?. Clinics 2006, 61:47-52.
29. Sillos Elaine M., Shenep Jerry L., Burghen George A., Pui Ching-Hon, Behm Frederick G., Sandlund John T. Lactic acidosis: A metabolic complication of hematologic malignancies. Cancer 2001, 92:2237-2246.
30. Flombaum C.D. Metabolic emergencies in the cancer patient. Semin Oncol 2000, 27:322-334.
31. Dobyan D.C., Levi J., Jacobs C., Kosek J., Weiner M.W. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980, 213:551-556.
32. Skinner R., Pearson A.D., English M.W., Price L., Wyllie R.A., Coulthard M.G., et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996, 348:578-580.
33. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11:694-703.
34. Ortega M., Rovira M., Almela M., de la Bellacasa J.P., Carreras E., Mensa J Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 2004, 33:741-744.
35. El-Maghraby S.M., Moneer M.M., Ismail M.M., Shalaby L.M., El-Mahallawy H.A. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol 2007, 29:131-136.
36. Uys A., Rapoport B.L., Fickl H., Meyer P.W., Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 2007, 16:475-483.
37. Legouffe E., Rodriguez C., Picgt M.C., Richard B., Klein B., Rossi J.F., et al. C-reactive protein serum level is a valuable and simple prognostic marker in Non Hodgkin's lymphoma. Leukemia Lymphoma 1998, 31:351-357.
38. Murri A.M.A., Bartlett J.M.S., Canney P.A., Doughty J.C., Wilson C., McMillan D.C. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006, 94:227-230.
39. Ramsey S., Lamb G.W.A., Aitchison M., Graham J., McMillan D.C. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007, 109:205-212.
40. Sharma R., Hook J., Kumar M., Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008, 44:251-256.
41. Kato H., Kinoshita T., Suzuki S., Nagasaka T., Murate T., Saito H., et al. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration. Br J Hematol 1996, 92:1014-1021.
42. Voorzanger N., Touitou R., Garcia E., Delecluse H.-J., Rousset F., Joab I., et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996, 56:5499-5505.
43. Artz A.S., Wickrema A., Dinner S., Godley L.A., Kocherginsky M., Odenike O., et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1209-1216.
44. Choi C.W., Sung H.J., Park K.H., Yoon S.Y., Kim S.J., Oh S.C., et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003, 73:263-266.
45. Massaro K.S., Costa S.F., Leone C., Chamone D.A. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 2007, 7:137.
46. Vekemans M., Robinson J., Georgala A., Heymans C., Muanza F., Paesmans M., et al. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis 2007, 44:1593-1601.